Back

Adverse event profiles after brand or generic clopidogrel in the Food and Drug Administration Adverse Event Reporting System (FAERS)

26 August 2018 (15:24 - 15:45)
Organised by:
Congress Presentation Part of: Safety issues with anti-platelets drugs Antiplatelet Drugs ESC Premium Access ESC Congress 2018

About the speaker

Photo
Associate Professor Victor L Serebruany

Johns Hopkins University, Baltimore (United States of America)

3 More presentations in this session

Presentation thumbnail
Perceived or calculated bleeding risk in patients undergoing percutaneous coronary intervention: inside the post-pci prospective registry
Doctor M. Ferlini (Pavia, IT)
Abstract
Presentation thumbnail
Are perceived or calculated bleeding risk related to dapt choice in patients undergoing percutaneous coronary intervention?
Doctor M. Ferlini (Pavia, IT)
Abstract
Presentation thumbnail
Platelet inhibition on brand and generic clopidogrel chronic therapy
Doctor A. Soliman (Dammam, SA)
Abstract Slides Video

Access the full session

Session thumbnail
Safety issues with anti-platelets drugs

The Event

Event poster

ESC Congress 2018

26 August 2018 15:24 CET
You may be interested in
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Presentation
Optimizing antiplatelet therapy in ACS: a network meta-analysis of simplified regimens
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources